New hope for rare melanomas? drug combo enters phase 2 trial

This study tests a combination of two experimental drugs (iparomlimab and tuvoraleimab) plus standard chemotherapy for people with advanced acral or mucosal melanoma, rare and aggressive skin cancers. About 48 adults who have had little or no prior treatment will receive the therapy to see if it shrinks tumors. The goal is to control the disease, not cure it, as ongoing management is expected.